Abcam, ab273862, Human TAL1 knockout Jurkat cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
TAL1 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9 X = 2 bp insertion Frameshift: 100%. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:Jurkat,
Species or organism:Human,
Tissue:Blood,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 2 bp insertion Frameshift: 100%,
Disease:Non-Hodgkin Lymphoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-TAL1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein Tal1 also known as T-cell acute lymphocytic leukemia protein 1 and SCL (stem cell leukemia) is a transcription factor of about 34 kDa. It plays a role in the regulation of hematopoiesis. Tal1 is expressed in hematopoietic cells and tissues like bone marrow thymus and fetal liver. It binds to specific DNA sequences to regulate gene expression essential for the development and function of blood cells.
Biological function summary
The Tal1 protein controls the differentiation and proliferation of hematopoietic stem cells and progenitor cells. It participates as a part of a multiprotein complex involving other transcription factors and cofactors such as GATA-1 and LMO2 which modulates gene expression during blood cell lineage commitment. Through these interactions Tal1 influences both myeloid and lymphoid lineage differentiation.
Pathways
Tal1 acts as an important regulator in the hematopoietic development pathway and is critical for the endothelial-to-hematopoietic transition. This transition is supported by interaction with the E2A proteins which stabilize the formation of the transcription complex needed for lineage-specific gene regulation. Tal1 also plays a role in the VEGF signaling pathway impacting vascular and blood development processes.
Tal1 significantly associates with T-cell acute lymphoblastic leukemia (T-ALL) and some types of anemia. Its deregulation often through chromosomal translocations or overexpression results in aberrant hematopoiesis contributing to leukemogenesis. In T-ALL Tal1 can interact with oncogenic proteins like LMO1 and LMO2 leading to the disruption of normal T-cell development and proliferation highlighting its involvement in the disease's molecular pathology.